Does the media refer more to SGP or TARS?

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Spyglass Pharma. MarketBeat recorded 8 mentions for Tarsus Pharmaceuticals and 5 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 0.59 beat Tarsus Pharmaceuticals' score of 0.33 indicating that Spyglass Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer RGC or SGP?

Spyglass Pharma has a consensus target price of $44.00, suggesting a potential upside of 76.57%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Spyglass Pharma is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Spyglass Pharma 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has higher earnings and valuation, RGC or SGP?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Spyglass Pharma N/A N/A -$39.87M -$7.00 N/A

Is RGC or SGP more profitable?

Regencell Bioscience's return on equity of 0.00% beat Spyglass Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Spyglass Pharma N/A -62.40% -24.83%

Does the media prefer RGC or SGP?

In the previous week, Spyglass Pharma had 2 more articles in the media than Regencell Bioscience. MarketBeat recorded 5 mentions for Spyglass Pharma and 3 mentions for Regencell Bioscience. Spyglass Pharma's average media sentiment score of 0.59 beat Regencell Bioscience's score of 0.33 indicating that Spyglass Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Spyglass Pharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MOR or SGP?

Spyglass Pharma has a consensus target price of $44.00, suggesting a potential upside of 76.57%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Spyglass Pharma is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Spyglass Pharma 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is MOR or SGP more profitable?

Spyglass Pharma has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Spyglass Pharma's return on equity of -62.40% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Spyglass Pharma N/A -62.40% -24.83%

Which has higher valuation & earnings, MBX or SGP?

MBX Biosciences is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MBX Biosciences N/A N/A -$86.97M -$2.41 N/A Spyglass Pharma N/A N/A -$39.87M -$7.00 N/A

Is MBX or SGP more profitable?

MBX Biosciences' return on equity of -26.02% beat Spyglass Pharma's return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -26.02% -24.94% Spyglass Pharma N/A -62.40% -24.83%

Does the media refer more to MBX or SGP?

In the previous week, Spyglass Pharma had 3 more articles in the media than MBX Biosciences. MarketBeat recorded 5 mentions for Spyglass Pharma and 2 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.16 beat Spyglass Pharma's score of 0.59 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyglass Pharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SGP or SUPN?

In the previous week, Spyglass Pharma and Spyglass Pharma both had 5 articles in the media. Spyglass Pharma's average media sentiment score of 0.59 beat Supernus Pharmaceuticals' score of -0.46 indicating that Spyglass Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Spyglass Pharma (SGP) Competitors

$24.92 +0.30 (+1.22%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$25.11 +0.19 (+0.76%)

As of 10/9/2026 07:30 PM Eastern

Compare

SGP vs. TARS, RGC, MOR, MBX, and SUPN

Should you buy Spyglass Pharma stock or one of its competitors? Spyglass Pharma's main competitors and comparable companies include Tarsus Pharmaceuticals (TARS), Regencell Bioscience (RGC), MorphoSys (MOR), MBX Biosciences (MBX), and Supernus Pharmaceuticals (SUPN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Spyglass Pharma compare to Tarsus Pharmaceuticals?

Spyglass Pharma (NASDAQ:SGP) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Spyglass Pharma has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Tarsus Pharmaceuticals' return on equity of -13.53% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	-62.40%	-24.83%
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Spyglass Pharma. MarketBeat recorded 8 mentions for Tarsus Pharmaceuticals and 5 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 0.59 beat Tarsus Pharmaceuticals' score of 0.33 indicating that Spyglass Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spyglass Pharma currently has a consensus price target of $44.00, indicating a potential upside of 76.57%. Tarsus Pharmaceuticals has a consensus price target of $100.86, indicating a potential upside of 37.86%. Given Spyglass Pharma's higher probable upside, analysts plainly believe Spyglass Pharma is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Tarsus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Spyglass Pharma has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A
Tarsus Pharmaceuticals	$451.36M	7.11	-$66.42M	-$1.09	N/A

Summary

Tarsus Pharmaceuticals beats Spyglass Pharma on 9 of the 14 factors compared between the two stocks.

How does Spyglass Pharma compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Spyglass Pharma (NASDAQ:SGP) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A

Regencell Bioscience's return on equity of 0.00% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Spyglass Pharma	N/A	-62.40%	-24.83%

In the previous week, Spyglass Pharma had 2 more articles in the media than Regencell Bioscience. MarketBeat recorded 5 mentions for Spyglass Pharma and 3 mentions for Regencell Bioscience. Spyglass Pharma's average media sentiment score of 0.59 beat Regencell Bioscience's score of 0.33 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyglass Pharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyglass Pharma has a consensus target price of $44.00, suggesting a potential upside of 76.57%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Spyglass Pharma is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

0.1% of Regencell Bioscience shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Regencell Bioscience and Spyglass Pharma tied by winning 5 of the 10 factors compared between the two stocks.

How does Spyglass Pharma compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Spyglass Pharma (NASDAQ:SGP) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

In the previous week, Spyglass Pharma had 5 more articles in the media than MorphoSys. MarketBeat recorded 5 mentions for Spyglass Pharma and 0 mentions for MorphoSys. Spyglass Pharma's average media sentiment score of 0.59 beat MorphoSys' score of 0.00 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Spyglass Pharma	Positive

Spyglass Pharma has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Spyglass Pharma's return on equity of -62.40% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Spyglass Pharma	N/A	-62.40%	-24.83%

Spyglass Pharma has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A

Spyglass Pharma has a consensus target price of $44.00, suggesting a potential upside of 76.57%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Spyglass Pharma is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

18.4% of MorphoSys shares are held by institutional investors. 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Spyglass Pharma beats MorphoSys on 9 of the 14 factors compared between the two stocks.

How does Spyglass Pharma compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Spyglass Pharma (NASDAQ:SGP) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

In the previous week, Spyglass Pharma had 3 more articles in the media than MBX Biosciences. MarketBeat recorded 5 mentions for Spyglass Pharma and 2 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.16 beat Spyglass Pharma's score of 0.59 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyglass Pharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBX Biosciences' return on equity of -26.02% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Spyglass Pharma	N/A	-62.40%	-24.83%

MBX Biosciences is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A

MBX Biosciences currently has a consensus target price of $83.89, suggesting a potential upside of 57.57%. Spyglass Pharma has a consensus target price of $44.00, suggesting a potential upside of 76.57%. Given Spyglass Pharma's higher probable upside, analysts clearly believe Spyglass Pharma is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

MBX Biosciences beats Spyglass Pharma on 6 of the 11 factors compared between the two stocks.

How does Spyglass Pharma compare to Supernus Pharmaceuticals?

Spyglass Pharma (NASDAQ:SGP) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Supernus Pharmaceuticals has higher revenue and earnings than Spyglass Pharma. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A
Supernus Pharmaceuticals	$718.95M	3.46	-$38.55M	-$1.92	N/A

In the previous week, Spyglass Pharma and Spyglass Pharma both had 5 articles in the media. Spyglass Pharma's average media sentiment score of 0.59 beat Supernus Pharmaceuticals' score of -0.46 indicating that Spyglass Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spyglass Pharma has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	-62.40%	-24.83%
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

Spyglass Pharma presently has a consensus target price of $44.00, suggesting a potential upside of 76.57%. Supernus Pharmaceuticals has a consensus target price of $62.40, suggesting a potential upside of 46.24%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Spyglass Pharma is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Supernus Pharmaceuticals	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

Summary

Spyglass Pharma beats Supernus Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Get Spyglass Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGP vs. The Competition

Export

Metric	Spyglass Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$823.12M	$12.35B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-3.56	797.58	274.15	26.16
Price / Sales	N/A	757.87	589.97	94.50
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	N/A	10.71	11.21	6.34
Net Income	-$39.87M	$2.84B	$3.50B	$381.90M
7 Day Performance	N/A	-0.93%	-0.90%	-1.41%
1 Month Performance	-8.75%	-4.91%	-4.44%	-3.48%
1 Year Performance	N/A	-4.13%	6.96%	1.16%

Spyglass Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGP Spyglass Pharma	3.1488 of 5 stars	$24.92 +1.2%	$44.00 +76.6%	N/A	$823.12M	N/A	N/A	65	Positive News
TARS Tarsus Pharmaceuticals	3.5721 of 5 stars	$76.28 -0.7%	$100.86 +32.2%	+3.9%	$3.35B	$451.36M	N/A	50	Analyst Downgrade
RGC Regencell Bioscience	0.389 of 5 stars	$6.16 -0.7%	N/A	-60.1%	$3.04B	N/A	N/A	10	News Coverage Earnings Report
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
MBX MBX Biosciences	3.0206 of 5 stars	$57.68 +0.2%	$77.00 +33.5%	+235.7%	$2.77B	N/A	N/A	63	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGP) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spyglass Pharma (SGP) Competitors

SGP vs. TARS, RGC, MOR, MBX, and SUPN

How does Spyglass Pharma compare to Tarsus Pharmaceuticals?

Summary

How does Spyglass Pharma compare to Regencell Bioscience?

Summary

How does Spyglass Pharma compare to MorphoSys?

Summary

How does Spyglass Pharma compare to MBX Biosciences?

Summary

How does Spyglass Pharma compare to Supernus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGP vs. The Competition

Spyglass Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spyglass Pharma (SGP) Competitors

SGP vs. TARS, RGC, MOR, MBX, and SUPN

How does Spyglass Pharma compare to Tarsus Pharmaceuticals?

Is SGP or TARS more profitable?

Does the media refer more to SGP or TARS?

Do analysts prefer SGP or TARS?

Do institutionals & insiders believe in SGP or TARS?

Which has better earnings and valuation, SGP or TARS?

Summary

How does Spyglass Pharma compare to Regencell Bioscience?

Which has higher earnings and valuation, RGC or SGP?

Is RGC or SGP more profitable?

Does the media prefer RGC or SGP?

Do analysts prefer RGC or SGP?

Do institutionals and insiders hold more shares of RGC or SGP?

Summary

How does Spyglass Pharma compare to MorphoSys?

Does the media refer more to MOR or SGP?

Is MOR or SGP more profitable?

Which has better earnings and valuation, MOR or SGP?

Do analysts recommend MOR or SGP?

Do insiders & institutionals hold more shares of MOR or SGP?

Summary

How does Spyglass Pharma compare to MBX Biosciences?

Does the media refer more to MBX or SGP?

Is MBX or SGP more profitable?

Which has higher valuation & earnings, MBX or SGP?

Do analysts rate MBX or SGP?

Summary

How does Spyglass Pharma compare to Supernus Pharmaceuticals?

Which has higher valuation and earnings, SGP or SUPN?

Does the media prefer SGP or SUPN?

Is SGP or SUPN more profitable?

Do analysts rate SGP or SUPN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGP vs. The Competition

Spyglass Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools